Jefferies Group Weighs in on DBV Technologies SA -‘s Q4 2017 Earnings (DBVT)

DBV Technologies SA – (NASDAQ:DBVT) – Analysts at Jefferies Group issued their Q4 2017 earnings estimates for DBV Technologies in a research report issued on Thursday. Jefferies Group analyst E. Yang anticipates that the company will post earnings of ($1.14) per share for the quarter. Jefferies Group currently has a “Buy” rating and a $51.00 target price on the stock.

A number of other equities research analysts also recently issued reports on DBVT. Zacks Investment Research upgraded shares of DBV Technologies from a “hold” rating to a “buy” rating and set a $50.00 target price for the company in a report on Tuesday, August 29th. ValuEngine downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Citigroup boosted their price objective on shares of DBV Technologies from $43.00 to $57.00 and gave the stock a “buy” rating in a research note on Monday, October 2nd. Morgan Stanley reissued an “overweight” rating and set a $72.00 target price (up from $70.00) on shares of DBV Technologies in a research report on Friday, October 6th. Finally, Deutsche Bank boosted their target price on shares of DBV Technologies from $46.00 to $56.00 in a research report on Sunday, October 8th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $49.63.

Shares of DBV Technologies (DBVT) traded up $0.48 during midday trading on Monday, hitting $23.87. 82,400 shares of the stock were exchanged, compared to its average volume of 220,571. DBV Technologies has a 1-year low of $20.58 and a 1-year high of $50.57.

Hedge funds and other institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC purchased a new stake in DBV Technologies during the third quarter valued at about $132,000. Quantbot Technologies LP purchased a new stake in DBV Technologies during the third quarter valued at about $146,000. Commonwealth Equity Services Inc purchased a new stake in DBV Technologies during the third quarter valued at about $233,000. Dynamic Technology Lab Private Ltd purchased a new stake in DBV Technologies during the second quarter valued at about $222,000. Finally, Belpointe Asset Management LLC purchased a new stake in DBV Technologies during the third quarter valued at about $343,000. 46.92% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/12/27/jefferies-group-weighs-in-on-dbv-technologies-sa-s-q4-2017-earnings-dbvt.html.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Earnings History and Estimates for DBV Technologies (NASDAQ:DBVT)

What are top analysts saying about DBV Technologies? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DBV Technologies and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit